{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-244201","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.114788+00:00","generated_at":"2026-05-30T10:04:00.225055+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Intellia Phase 2 NTLA-2002: 8/11 patients attack-free after single dose; 77% attack reduction vs placebo","bullets":["Mean monthly attack rate reduced by 77% (50 mg) vs placebo during weeks 1-16; 81% during weeks 5-16.","Eight of 11 patients in 50 mg arm had zero attacks over 16 weeks and remained attack-free through median 8-month follow-up.","Kallikrein protein reduction: 86% mean reduction from baseline at week 16 (50 mg) vs 55% (25 mg).","Well-tolerated; no serious AEs in NTLA-2002 arms; most common AEs were headache, fatigue, nasopharyngitis.","50 mg dose selected for global Phase 3 HAELO study, which is actively screening patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-244201","json":"https://secwatch.observer/filing/0001193125-24-244201.json","markdown":"https://secwatch.observer/filing/0001193125-24-244201.md","text":"https://secwatch.observer/filing/0001193125-24-244201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524244201/0001193125-24-244201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524244201/d842130d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:04:00.225055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}